also demonstrated that JAK/STAT inhibition with tofacitinib selectively modulates ILC1-driven IFN-γ production in RA patients, highlighting therapeutic potential for targeting specific ILC functions (131). Here, CCL27 is linked to rheumatoid arthritis.